Skip to content
Precision for Medicine
Contact Us

Announcing the Institute@Precision, a Collaborative Forum for Biopharma Innovation.

Explore the Institute@Precision
target-expression-xpressway_header target-expression-xpressway_header-mobile

Whole Body Target Expression –XpressWay™ Profiles

Understanding how a therapeutic candidate may impact different systems throughout the human body can help to make more informed development decisions
Using a set of 72 non-diseased human tissues and a validated quantitative reverse transcription-polymerase chain reaction (qRT-PCR) methodology to profile gene expression, Precision has developed XpressWay™ Profiles, a robust, quantitative platform to provide insight into whole body target expression.

XpressWay™ Profiles for target expression

Precision's established XpressWay Profile database contains profiles for more than 2,300 genes, which enables immediate access to robust data for your target(s) of interest. In addition, we can rapidly generate these data profiles for new targets and/or variants on demand.

Capabilities


  • Target validation
  • Safety liability
  • Drug repurposing
  • Validation of animal models
  • 2,300 existing gene profiles available

 

Advantages


  • qRT-PCR based for sensitive and quantitative expression data
  • Validated and robust methodology
  • Existing profiles can be leveraged for rapid data delivery, or new profiles can be generated
XpressWay Profiles Example (1)

XpressWay™ Profiles deliver data on how therapeutics may impact tissue and organ systems

Data are generated using 72 non-diseased tissues representing all core organ systems, each tissue from n=3 independent donors. 

This helps provide both a broad and deep understanding of potential physiological impact of a candidate therapeutic.

Scientific in lab

Choose a contract research organization with Precision

A contract research organization (CRO) is crucial to medical research and development to provide support that includes clinical trial management and CRO research. The right outsourced CRO services can accelerate the overall process of drug development and market placement. Whether you need a CRO for clinical trials or a CRO for pharma, Precision has a solution that can be tailored to the needs of your study.

What sets Precision apart from other contract research organizations, is the way we integrate clinical trial execution with deep scientific knowledge, laboratory expertise, and advanced data sciences. This is Precision Convergence: maximizing insights into patient biology and accelerating the pace of scientific discovery and approval.

Related services

  • Explore
    IHC
    tissue-slide

    IHC

    End-to-end IHC solutions including kitting, sample logistics, staining via all major platforms, and in-house pathology services
    Explore
    tissue-slide

    IHC

    End-to-end IHC solutions including kitting, sample logistics, staining via all major platforms, and in-house pathology services
    Explore
  • Explore
    Multiplex

    Multiplex Immuno-fluorescence

    Automated multiplex immunofluorescence services that enable quantitative visualization of up to 9 markers in tissue and liquid biopsies
    Explore

    Multiplex Immuno-fluorescence

    Automated multiplex immunofluorescence services that enable quantitative visualization of up to 9 markers in tissue and liquid biopsies
    Explore
  • Explore

    Pathology Services

    In-house pathology team to provide expert assessments with rapid turn-around times, and sample processing services including FFPE and microdissection
    Explore

    Pathology Services

    In-house pathology team to provide expert assessments with rapid turn-around times, and sample processing services including FFPE and microdissection
    Explore

Explore the Precision blog

Read our blog to gain more insights and discover work that Precision has supported.

Explore our blog
Read: Reflect on 20 Years of Cancer Research with MIRROR Biospecimens Reflect on 20 Years of Cancer Research with MIRROR Biospecimens

Translational Research - Biospecimens

Reflect on 20 Years of Cancer Research with MIRROR Biospecimens

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=199448088864, hs_child_table_id=0, hs_updated_at=1762810484868, hs_published_at=1763063316762, avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Kaylee%20Mueller.png',altText='Kaylee Mueller',fileId=199456336149}, lastname=Mueller, hs_initial_published_at=1762810487482, hs_created_by_user_id=26433386, hs_created_at=1762810467146, hs_is_edited=false, hs_deleted_at=0, name=Kaylee, slug=kaylee-mueller, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Kaylee Mueller avatar

    Kaylee Mueller
Discover
Read: Lost in Translation: Turning Multi-omic Chaos into Clinical Clarity Lost in Translation: Turning Multi-omic Chaos into Clinical Clarity

Translational Research - Lab Services

Lost in Translation: Turning Multi-omic Chaos into Clinical Clarity

|
    has third author: false, (SizeLimitingPyMap: {main={hs_id=159488778872, hs_child_table_id=0, hs_updated_at=1744653337128, hs_published_at=1763063316762, description=Visionary leader with decades of distinguished biotechnology and clinical translational research experience. Founded ApoCell in 2004 and later was instrumental in developing and commercializing the ApoStream® rare-cell liquid biopsy technology. Globally recognized cancer researcher and the author of more than 100 peer-reviewed publications. Dedicated and committed to improving the lives of patients with debilitating diseases., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Darren%20Davis.webp',altText='Darren Davis',fileId=165891429693}, linkedin=https://www.linkedin.com/in/drdarrendavis, team=[{id=163072475009, name='Translational Sciences Leadership'}], hs_name=, hs_path=, lastname=Davis, PhD, hs_initial_published_at=1763062961222, hs_created_at=1709645745103, hs_is_edited=false, hs_deleted_at=0, name=Darren, job=Senior Vice President, Translational Sciences, slug=darren-davis, email=, hs_updated_by_user_id=26433386}, second={hs_id=167888548278, hs_child_table_id=0, hs_updated_at=1722451546286, hs_published_at=1763063316762, description=Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Deb%20Phippard.webp',altText='Deb Phippard',fileId=165892372605}, linkedin=https://www.linkedin.com/in/deb-phippard-103b54, team=[{id=163072475009, name='Translational Sciences Leadership'}], hs_name=, hs_path=, lastname=Phippard, PhD, hs_initial_published_at=1716194887110, hs_created_by_user_id=2737751, hs_created_at=1716194842710, hs_is_edited=false, hs_deleted_at=0, name=Deborah, job=Chief Scientific Officer, slug=deborah-phippard-translational-sciences, email=, hs_updated_by_user_id=26433386}, third={hs_id=159488778883, hs_child_table_id=0, hs_updated_at=1762803857448, hs_published_at=1763063316762, description=Jie Yang, PhD is a Scientific Liaison for Precision for Medicine. An Immunologist by training with extensive industry expertise in designing translational assays for biomarker-guided clinical trials. Conducted postdoctoral research on immuno-oncology at MD Anderson Cancer Center. Led biomarker assay development and collaborated on the implementation of new technologies for pre-clinical and clinical studies conducted by pharmaceutical and biotech companies for drug development., avatar=Image{width=885,height=886,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Jie-Yang.png',altText='Jie-Yang',fileId=167372215352}, linkedin=https://www.linkedin.com/in/jie-yang-0528221b, hs_name=, hs_path=, lastname=Yang, PhD, hs_initial_published_at=1763062961222, hs_created_at=1709645745114, hs_is_edited=false, hs_deleted_at=0, name=Jie, job=, slug=jie-yang, email=, hs_updated_by_user_id=26433386}})
  • Darren D. avatar Deborah P. avatar Jie Y. avatar

  • Darren D.

    Deborah P.

    Jie Y.
Discover
Read: Investor Relations, Clinical Operations, and the Future of Biotech Financing Investor Relations, Clinical Operations, and the Future of Biotech Financing

Clinical Trials - Translational Research - Early Phase Research

Investor Relations, Clinical Operations, and the Future of Biotech Financing

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548862, hs_child_table_id=0, hs_updated_at=1716454315513, hs_published_at=1763063316762, description=Teresa is a respected business development strategist, building successful clinical programs for clients in Massachusetts. She is an innovator of fresh approaches to biomarker planning, translational solutions, and clinical study design. Her experience spans the execution of Phase 1-4 clinical trials, specialty lab services, companion and in vitro diagnostic strategies, and biomarker data management., avatar=Image{width=700,height=700,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Teresa-Pokladowski-300x300.png',altText='Teresa-Pokladowski-300x300',fileId=168135942975}, linkedin=https://www.linkedin.com/in/teresapokladowski/, lastname=Pokladowski, hs_initial_published_at=1713363230550, hs_created_by_user_id=5166971, hs_created_at=1713362443509, hs_is_edited=false, hs_deleted_at=0, name=Teresa, job=Regional Vice President, Clinical Business Solutions, North America, slug=teresa-pokladowski, hs_updated_by_user_id=26433386}, second={hs_id=197608580658, hs_child_table_id=0, hs_updated_at=1760465121471, hs_published_at=1763063316762, description=Hannah Dereseiwicz is a strategic force in investor relations, helping biotech innovators translate complex science into compelling narratives that drive engagement and growth. With a track record spanning commercial launches, M&A activity, and high-stakes communications, she brings clarity, confidence, and momentum to every stage of a company’s journey. Hannah’s approach is defined by the three A’s—ambitious, approachable, and authentic—making her a trusted partner for teams looking to elevate their story and connect with the audiences that matter most., avatar=Image{width=636,height=476,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Hannah%20Deresiewicz.webp',altText='Hannah Deresiewicz',fileId=197608718507}, lastname=Deresiewicz, hs_initial_published_at=1760465283803, hs_created_by_user_id=26433386, hs_created_at=1760464991513, hs_is_edited=false, hs_deleted_at=0, name=Hannah, job=Executive Vice President, Managing Director Precision AQ – Investor Relations & External Communications, slug=hannah-deresiewicz, hs_updated_by_user_id=26433386}, third={}})
  • Teresa P. avatar

    Teresa P.
  • Hannah D. avatar

    Hannah D.
Discover
Loading...